Genmab — Maj 2018
-
-
Husk nu, at man som CEO i et børsnoteret selskab skal være varsom med offentlige kommentarer.
-
Tror faktisk, at de store partnerne er meget nidkære omkring kommunikationen omkring det de deltager i sammen med Genmab.
-
God morgen.:-)
-
Tak bibob...Sidder og skriver på min kommende investeringsbog. Genmab får sit helt eget kapitel.
-
this old Ofa
study has results posted - Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) - https://clinicaltrials.gov/ct2/history/NCT01191190?A=5&B=6&C=merged -
The DRd vs Rd Study Completion date 2 years earlier (why would they do that?) - https://clinicaltrials.gov/ct2/history/NCT02252172?A=45&B=46&C=merged
-
E L, in June last year they changed it from 2022 to 2024. Now they have changed it back to 2022. At the same time (June last year) they changed the end of study from maximum up to 5 years to 7 years. But as it is "up to" I guess they have now found out that the 7 years are not necessary.
-
Det bliver der bibob.
-
the extent of cell lysis was highest with ofatumumab, followed by rituximab and ocrelizumab. Ongoing studies in other B-cell cytotoxicity assays will provide a broader overview regarding relevant MoAs.
Conclusions: The strong complement-dependent B-cell lysis by ofatumumab may contribute to its high potency in vivo that enables a low-dose subcutaneous dosing regimen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind